Immunize to Build Broad HIV Antibodies
Official title: Inducing Broadly Neutralizing Antibodies to Protect Against HIV
Funded at San Diego Biomedical Research Institute · NIH-11510034 · Data updated 2026-11-12
A HIV vaccine grant tests new lab-made proteins and vaccines designed to help the immune system produce broadly protective antibodies for people at risk of HIV.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | San Diego Biomedical Research Institute NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project start | June 4, 2026 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $809,479 |
| NIH project number | 1R56AI197990-01A1 |
| Project ID | NIH-11510034 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals at risk for HIV who could participate in future vaccine trials or immunology studies.
✕Less likely to help
People not involved in HIV vaccine trials or who are not candidates for immunology studies may not directly benefit.
What this research studies
This project aims to prime and mature immune cells to create antibodies that cantarget a wide range of HIV strains. Researchers are using engineered HIV proteins and near-native Env structures to guide antibody development toward breadth. The work involves immunogens and boosting strategies that could be adapted for future vaccines in people at risk of AIDS. If successful, it could pave the way for vaccines that protect against diverse HIV variants.
Why it matters
Potential benefit: If successful, the research could lead to a vaccine capable of providing broad protection against many HIV strains.
How similar studies have gone: Past efforts showed progress in shaping immune responses, but broadly protective antibodies against HIV remain a challenge and this project seeks to advance that.
Where this research is happening
-
San Diego Biomedical Research Institute
San Diego, United States Active
Researchers
- Principal investigator: Binley, James M — San Diego Biomedical Research Institute
- Study coordinator: Binley, James M
Related research
Other NIH-funded projects on the same topics.
-
How cancer-linked pathways create fragile spots in DNA
This project looks at how cancer-related cellular pathways make weak spots in chromosomes so patterns in a tumor's genome can point to the pathways driving that cancer.
-
Cis-acting elements that control when DNA replication starts in development
Researchers are studying specific DNA sequences that help determine when and how quickly DNA replication happens in early cell development, with potential implications for cancer.
-
Nanoscale imaging of HIV Env complexes to improve NK cell antibody therapies
A study to better understand how HIV envelope immune complexes affect natural killer cell antibody therapies and how to design better antibodies.
-
Meth and HIV in the brain: how meth use may affect HIV latency and brain cells
A study to understand how methamphetamine use might change HIV behavior in brain cells and how that could influence HIV persistence and brain health in people living with HIV.
-
Role of a special interferon-responsive T cell in allergies and asthma
A study explores a unique interferon-responsive T cell type that may influence allergies and asthma, aiming to understand why some people become allergic and how this T cell subset could affect airway inflammation.
-
How methamphetamine affects HIV in the brain
This project looks at how methamphetamine changes where HIV hides and stays active in brain cells of people with HIV to help explain lasting brain problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.